Nitric oxide (Genosyl)
Other
Evidence outlook
Approved: Persistent Pulmonary Hypertension of the Newborn
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Persistent Pulmonary Hypertension of the Newborn: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nitric Oxide (Genosyl): this drug | Approved | Gas (inhaled, On-demand Generation) | Soluble guanylyl cyclase (sGC) | not yet graded | No reviewed efficacy summary in this indication | |
| Nitric Oxide (INOmax) | Approved | Gas (inhaled) | Nitric oxide | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.